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Abstract
Pneumococcal disease has a high global morbidity and mor-
tality. We report a case of a 63-year old female with a history
of vaccination with pneumococcal polysaccharide vaccine-23
(PPSV-23) who was transferred to a tertiary care facility with
fever and seizures due to an unknown etiology. The diag-
nosis of invasive pneumococcal disease (IPD) was based on
the identification of Streptococcus pneumoniae in the blood
(culture; serogroup 3) and cerebrospinal fluid (antigen) and
the finding of purulence under pressure at craniotomy. The
pneumococcal vaccine should provide protection from IPD.
The findings reported here display that IPD can overcome im-
munity proffered by the pneumococcal vaccine, especially in
patients with multiple comorbidities. This patient who had IPD
represents anyone with comorbidities which justify PPSV-23
vaccination, but in whom neither a second PPSV-23, nor a
PCV-13 vaccination is recommended prior to the age of 65
years.
Introduction
Historically, vaccination has reduced morbidity and
mortality from disease. A vaccine against Streptococ-
cus pneumoniae was developed in 1977 for 14 serotypes.
It was expanded to 23 serotypes in 1983 and is known
as pneumococcal polysaccharide vaccine (PPSV-23). In
2000, a conjugated version for children was created for
7 serotypes, known as pneumococcal conjugate vaccine
(PCV-7). It was only available in Europe. It was ex-
panded to 13 serotypes (PCV-13) in 2010 and available
in the US as well. The following year, it was approved
for adults. The unconjugated vaccine (PPSV-23) stimu-
lates B-cells which release IgM, while the pneumococ-
cal conjugate vaccine (PCV-13) also recruits helper T-
cells for a more robust and longer immune response.
For those who are candidates, in general, the PCV-13 is
administered first, followed by a PPSV-23 at least one
year later, which is repeated again by a PPSV-23 five
years later if a patient is asplenic or immunocompro-
mised (Table 1).[1–3] The pneumococcal vaccine has
been shown to reduce the rate of deaths due to inva-
sive pneumococcal disease (IPD).[4]
Most pneumococcal infection results in otitis media in
children, but it commonly causes pneumonia in adults
and can less commonly cause invasive pneumococcal
disease, which is a severe complication that may even
result in death. The World Health Organization esti-
mates that nearly 2 million people die each year from
this disease. Although approximately two thirds of the
deaths are among children, many of their infections are
linked to adults to whom it is transmitted. A bene-
fit of vaccinating children has been translated to older
adults.[5] The following case may represent a popula-
tion who have less than optimal protection against S.
pneumoniae despite being appropriately vaccinated ac-
cording to the Advisory Committee on Immunization
Practices (ACIP). (IRB# 140217, 19.0161)
Presentation
A 63-year-old female with a history of diabetes melli-
tus and cardiac-related comorbidities, but no asplenia
or immunosuppression, was found unresponsive in her
home after complaining of an ear ache for three days.
The patient was admitted to the outside hospital, ob-
tunded with a temperature of 39.4°C. She required me-
chanical intubation and ventilation after the onset of
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Table 1. Recommendations from the Advisory Committee on Immunization Practices (ACIP) for vaccination criteria with pneumococcal
polysaccharide vaccine-23 (PPSV-23) and pneumococcal conjugate vaccine-13 (PCV-13).[1]
TABLE. Medical Conditions or other indications for administration of 13 valent pneumococcal conjugate vaccine (PCV13), and indications
for 23-valent pneumococcal polysaccharide vaccine (PPSV23) administration and revaccination for adults aged ≥ 19 years,∗ by risk
group—Advisory Committee on Immunization Practices, United States, 2012
Risk group Underlying medical condition PCV13 PPSV23
Recommended Recommended Revaccination 5 yrsafter first dose
Immunocompetent
persons
Chronic heart disease† •
Chronic lung disease‡ •
Diabetes mellitus •
Cerebrospinal fluid leak • •
Cochlear implant • •
Alcoholism •




Sickle cell disease/ other hemaglobinopathy • • •
Congenital or acquired asplenia • • •
Immunocompromised
persons
Congenital or acquired immunodeficinecy§ • • •
Human immunodeficiency virus infection • • •
Chronic renal failure • • •
Nephrotic syndrome • • •
Leukemia • • •
Lymphoma • • •
Hodgkin disease • • •
Generalized malignancy • • •
Iastrogenic immunosuppression¶ • • •
Solid organ transplant • • •
Multiple myeloma • • •
∗All adults aged ≥ 65 years should receive a dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine;
†Including congestive heart failure and cardiomyopathies, excluding hypertension; ‡Including chronic obstructive pulmonary disease, em-
physema, and asthma; §Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4
deficiencies), and phagocytic disorders (excluding chronic granulomatous disease); ¶Diseases requiring treatment with immunosuppressive
drugs, including long-term systemic corticosteroids and radiation therapy.
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Figure 1. Chest X-ray at the time of admission showing a left lower lobe infiltrate.
generalized seizures and hypoxic respiratory failure. A
chest X-ray was abnormal with a left lower lobe infil-
trate (Figure 1).
The seizures were treated with phenytoin and leve-
tiracetam. She received empiric intravenous cefepime,
vancomycin and fluconazole. Cerebrospinal fluid anal-
ysis was consistent with bacterial meningitis—2700
nucleated cells/mL with 96% neutrophils, glucose
138 mg/dL (normal 40–70), and protein 155 mg/dL
(normal 10–45). Computed tomography scan of the
brain on the second day of admission revealed an
area suspicious for subarachnoid bleeding or subdu-
ral hematoma. The patient’s respiratory status im-
proved, and she was able to be extubated; however,
the fever and seizures continued. Cultures of the cere-
brospinal fluid were negative. Two blood cultures re-
vealed S. pneumoniae, MIC to penicillin G <0.03. She
was then transferred to our tertiary care hospital for
further workup and management. She had had a PPSV-
23 at age 61.
On initial evaluation, the patient was alert and ori-
ented to person, place, time and situation. She com-
plained of partial hearing loss that was worse on the
right, headache, confusion, and intermittent slurred
speech with right-sided weakness. Vital signs were
stable with a temperature of 36.8°C, blood pressure
131/46 mmHg, pulse 80 beats/min, respirations 20
breaths/min, and SaO2 92% on room air. Physical exam
revealed a ruptured right tympanic membrane with
dried blood present in the external auditory canal. The
left tympanic membrane was intact and nearly opaque
with minimal fluid. There was dysmetria of the right
hand noted in finger-to-nose testing with pronator drift
of the right arm. A non-contrasted MRI revealed left
subdural hematomas with a small amount of hemor-
rhage within the lateral ventricle (Figure 2). Contrasted
computed tomography scan of the temporal bones re-
vealed bilateral mastoiditis without bony destructive
changes. An electroencephalogram showed excessive
diffuse slowing of background activity, a nonspecific
indicator of cerebral dysfunction.
Diagnosis and Management
This patient had multiple concurrent diagnoses on ad-
mission: pneumonia, bilateral mastoiditis, meningi-
tis, subdural hematoma, seizure and streptococcal bac-
teremia. A urinary streptococcal antigen test was ap-
plied to the patient’s cerebrospinal fluid obtained from
the outside hospital, which was positive. Streptococ-
cal antigen in both urine and cerebrospinal fluid are
FDA-approved tests to detect the presence of pneumo-
coccal infection.[6] A repeat MRI of the brain with con-
trast revealed a new fluid collection versus blood prod-
ucts in the left frontal and parietal sulci and overlying
subdural collection (Figure 3). In the setting of bilat-
eral mastoiditis complicated by confirmed pneumococ-
cal meningitis, this collection was considered to be an
empyema with concern for developing cerebritis.[7, 8]
The neurosurgeons drilled two burr holes, one frontal
and one parietal, over the left convexity, releasing pu-
rulent discharge under pressure. The next day, the
otolaryngologists performed bilateral myringotomies
with aspiration, culture of middle ear fluid and tympa-
nostomy tube placement. After these procedures, her
seizures resolved. She was continued on oral levetirac-
etam for seizure prophylaxis. She was then adminis-
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Figure 2. A motion artifact degraded MRI of the brain without IV contrast. T2 FLAIR axial image showing left subdural hematoma measuring
5–6 mm in its greatest axial thickness with localized mass effect and associated scattered subarachnoid hemorrhage.
Figure 3. An MRI of the patient’s brain with IV contrast with axial T1 image (A) and coronal (B) images showing progressed proteinaceous
fluid in the left frontal and parietal sulci, with associated mild enhancement and some focal areas of restricted diffusion and overlying subdural
collection. Full mastoid air cells are also visible bilaterally (right greater than left) inferior to each ear canal (B).
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tered PCV-13. She was treated with intravenous peni-
cillin G for a total of six weeks with subsequent return
to base line mental status, improved motor strength
and ability to perform her activities of daily living.
Discussion
The proportion of candidates who are immunized is
low; in the US, for example, only 32% of adults ≥65
years have been vaccinated with PCV-13.[4] The CDC’s
Healthy People 2020 targets are 60% for adult candi-
dates aged 18–64, and 90% for adults ≥65 years.[9]
PCV-13 is recommended to everyone ≥65 years, fol-
lowed by PPSV-23 6–12 months later.[10] For persons
≥19, PCV-13 may be given if certain risk factors are
present (Table 1), followed by PPSV-23 only eight
weeks later.[1] A second PPSV-23 may be given prior
to age 65 years for asplenia (anatomic or functional) or
if immunocompromised. This case raises the question
of whether additional comorbidities should qualify a
patient for vaccination.
The current patient had IPD despite vaccination. Based
on her diagnosis of diabetes, she was a candidate for
a PPSV-23, which she received when she was approx-
imately 61 years old. She did not qualify for either a
second PPSV-23 or a PCV-13 with her risk factors. Al-
though the FDA approved PCV-13 for adults ≥50 years,
ACIP recommends it for adults ≥65 years. The case
patient was vaccinated with PCV-13 before leaving the
hospital with an intention for a subsequent PPSV-23
vaccination. This may be effective prevention against
IPD as well as pneumonia—two diagnoses that the pa-
tient may not live through should she acquire them
again.[11, 12]
A meta-analysis of randomized controlled trials, com-
paring the incidence of IPD in patients vaccinated with
PPSV-23 versus placebo, found a correlate of efficacy of
74% (95% confidence interval (CI) 56%–85%).[13] It also
placed the odds ratio of contracting IPD at 0.26 when
PPSV-23 had been given. This means that the odds of
acquiring IPD for someone who received PPSV-23 was
one-fourth that of someone who received a placebo. A
sub-group analysis performed from the meta-analysis
found that vaccine efficacy among adults with chronic
disease, as in the case patient described, appeared
poor in comparison to that in otherwise healthy adults.
Two other studies evaluated response to pneumococ-
cal vaccination. The first included over 2000 patients
and showed that overall vaccine efficacy (prevention of
IPD) was 48% within the first two years and decreased
to 15% by five years, giving an overall vaccine effi-
cacy of only 24% (95% CI 10–36).[14] The second was
a surveillance study of pneumococcal epidemiology in
the UK, which studied the effect during the use of PCV-
7 in children and later during the use of PVC-13.[15] It
found a 37% decrease in overall IPD, but there was an
increase in IPD due to non-PVC-13 serotypes from 3.85
per 100,000 to 7.97 per 100,000 population (2000–06 ver-
sus 2016–17).
The present patient received one PPSV-23 previously;
among the 23 serotypes that it includes was the one iso-
lated from her: serotype 3. As she had only received
one PPSV-23 more than two years prior to admission,
her level of protection would have been expected to
be ∼3000 mg antibody nitrogen/radioimmunoassay
compared to pre-vaccination levels of ∼1500 mg Ab
N/RIA and 1-month post-vaccination levels of ∼4000
Ab N/RIA.[16] Furthermore, pneumococcal conjugate
vaccines, like the one she received before leaving the
hospital, may offer more benefit than the polysaccha-
ride vaccine PPSV-23 alone.
A study in Germany evaluated the prevalence of IPD
and pneumococcal serotypes, including serotype 3,
during two periods when conjugated vaccines were
prescribed to children.[17] The first period was 2007–
10, during which time PCV-7 was used, which does not
include serotype 3. The second period was 2010–14,
during which time PVC-13 was used, which includes
serotype 3. The study showed that the prevalence of
IPD due to serotype 3 in adults increased during the
first period but remained the same during the second
period.
There are challenges to immunizing a population. The
first is that physicians may not offer to immunize, or
patients may decline immunization. Among 24 pa-
tients with IPD in our facility since 2013, at least 10
were not vaccinated (Table 2). The second challenge is
under-vaccination. Two patients had incomplete vac-
cination, in need of PCV-13 and their second PPSV-23
vaccine. The third challenge is administering PPSV-
23 before PCV-13. A more robust response has been
shown when PCV-13 precedes PPSV-23.[18] Among
our 23 patients, only three had a serotype that was not
included in either the PCV-13 or PPSV-23 vaccine. The
most common serotype was 9V, which is in both pneu-
mococcal vaccines.
This case highlights that patients such as this may ben-
efit from additional pneumococcal vaccinations despite
not being indicated by the current ACIP guidelines.
There are a few revisions to the indications for pneu-
mococcal vaccinations that should be considered. First,
for patients with multiple co-morbidities who qualify
for a PPSV-23 and have some degree of immunosup-
pression, PCV-13 and a second PPSV-23 should also be
indicated. Furthermore, all of the conditions that qual-
ify a patient of 19–64 years to be a candidate for PPSV-
23 should also qualify a patient for PCV-13. A poten-
tial compromise would be for ACIP to lower the age at
which it recommends PCV-13 from ≥65 years to ≥50
years to match the approval by the FDA.
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Table 2. Serotype and vaccination history among other patients with invasive pneumococcal dis-
ease in this hospital over the last seven years.
Subject No. Year Culture Source Serotype Prior PPSV-23 Prior PCV-13
1 2013 Blood 11 N/A N/A
2 2013 Brain abscess 3 N/A N/A
3 2013 Blood, CSF 12B N/A N/A
4 2013 N/A 15 N/A N/A
5 2013 Blood 3 Yes, 1 of 1 No
6 2014 Blood 9V No No
7 2015 N/A 23F N/A N/A
8 2015 Blood 9V N/A N/A
9 2016 Blood 9V N/A N/A
10 2016 Sputum 19F Yes, 2 of 2 Yes
11 2016 Blood 15 No No
12 2016 Blood, CSF 20 No No
13 2016 Blood 22 No No
14 2017 Blood, CSF 19A No No
15 2017 Blood 9V Yes, 2 of 2 Yes
16 2017 Blood 20 N/A No
17 2018 Blood 35 No No
18 2019 Blood 7 No No
19 2019 Blood 15 Yes, 1 of 1 No
20 2019 Blood, CSF 20 No No
21 2019 Blood 9V No No
22 2019 Blood, CSF 23F No Yes
23 2019 Blood, CSF 35 No No
24 2019 Blood 12B Yes Yes
Conclusion
This patient had been vaccinated with PPSV-23 as rec-
ommended by ACIP but developed pneumonia and
IPD due to S. pneumoniae serotype 3. She represents
one of several people in our hospital, as well as a larger
population, who needs disease prevention the most,
but in whom neither a second PPSV-23 nor a PCV-13
is recommended prior to age 65 years. Reconsidering
which comorbidities justify additional vaccination may
be beneficial.
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